A Golden Ticket award offers entrepreneurial scientists or emerging biotechnology startups one-year usage of LabCentral's state-of-the-art lab facility in
AXONIS and Tenza were chosen for the strength of the innovation in their approach, the therapeutic potential of their research and alignment of their novel technological platforms with Astellas' research and development (R&D) Focus Areas.
'In awarding these Golden Tickets, we are reinforcing Astellas' ongoing commitment to discovering and advancing innovative science for the potential future benefit of patients worldwide,' said Maruyama, President, AVM. 'We applaud the efforts of AXONIS and Tenza in the advancement of potential treatments for CNS disorders and mucosal disease respectively, and we look forward to helping them realize their potential in these complex and underserved therapeutic areas.'
'We are honored to be awarded an Astellas Golden Ticket,' said Joanna Stanicka, Ph.D., CEO of AXONIS. 'Combining Astellas' CNS disorder expertise with LabCentral's exciting incubator space will further validate our KCC2-targeted programs that we are investigating to treat not only spinal cord injuries but a host of other neurological conditions in areas of high unmet patient need.'
Tenza is developing orally available therapeutics for mucosal disease by engineering probiotic microbes to produce and deliver drugs directly to gut tissue - with the goal of boosting bioavailability and therapeutic efficacy while reducing systemic side effects.
'Gaining access to Astellas' R&D and clinical expertise is a fantastic opportunity, for which we are most grateful,' said
'We are very pleased by Astellas' support of LabCentral and the Golden Ticket program,' said
Both AXONIS and Tenza will continue their residence at LabCentral with the next year sponsored by Astellas. Both will be closely supported by the team from AVM and the Astellas Biomedical Innovation Hub organizations in the
About the
Astellas' sponsorship of the
About
AVM is the wholly-owned venture capital organization within Astellas, dedicated to supporting pre-clinical, cutting-edge science that can bring VALUE to patients. For over 20 years, AVM has provided equity investments to private, early-stage companies developing therapeutic programs and platform technologies, helping them to advance their innovations faster. AVM is a strategic investor, making investments in science that will enhance the current Astellas R&D pipeline or that could catalyze new directions in discovery research.
About Astellas
About LabCentral
A private, non-profit institution, LabCentral was founded in 2013 as a launchpad for high-potential life sciences and biotech start-ups. Operating a total of 100,000 square-feet in the heart of
Cautionary Notes
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.
Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.
Contact:
Tel: +1 508-714-6817
Email: jarrod.aldom@astellas.com
(C) 2020 Electronic News Publishing, source